Back to Search
Start Over
Investigating Glioblastoma Angiogenesis Using A 3D in Vitro GelMA Microwell Platform.
- Source :
-
IEEE transactions on nanobioscience [IEEE Trans Nanobioscience] 2016 Apr; Vol. 15 (3), pp. 289-93. Date of Electronic Publication: 2016 Mar 25. - Publication Year :
- 2016
-
Abstract
- Angiogenesis is an indispensable mechanism in physiological and pathological development of tumors that requires an adequate blood supply. Therefore, understanding the angiogenesis mechanism of tumors has become an important research area to develop reliable and effective therapies for the treatment of tumors. Although several in vivo and in vitro models were developed and used to study the underlying mechanism of angiogenesis, they showed limited success. Therefore, there is an urgent need to build a stable and cost-effective three-dimensional (3D) in vitro angiogenesis model to investigate the tumor formation. In this study, we designed a 3D in vitro angiogenesis model based on gelatin methacrylate (GelMA) hydrogel microwells to mimic an in vivo-like microenvironment for co-cultured glioblastoma and endothelial cells. Our results confirmed the in vitro formation of microtubules during the angiogenic process. We believe that our cost-effective platform can be used for the high-throughput screening of anti-angiogenesis drugs and even for the development of better treatment strategies.
- Subjects :
- Cell Line, Tumor
Glioblastoma physiopathology
Human Umbilical Vein Endothelial Cells
Humans
Neovascularization, Pathologic physiopathology
Spheroids, Cellular
Tumor Cells, Cultured
Coculture Techniques methods
Gelatin chemistry
Glioblastoma pathology
Methacrylates chemistry
Neovascularization, Pathologic pathology
Tissue Culture Techniques methods
Subjects
Details
- Language :
- English
- ISSN :
- 1558-2639
- Volume :
- 15
- Issue :
- 3
- Database :
- MEDLINE
- Journal :
- IEEE transactions on nanobioscience
- Publication Type :
- Academic Journal
- Accession number :
- 27046878
- Full Text :
- https://doi.org/10.1109/TNB.2016.2528170